In this study, we investigated the prognostic value of the plasma concentrations of VEGF family members in patients with metastatic HER2-negative breast cancer who were treated with a first-line taxane-bevacizumab chemotherapy combination. The gene discussed is VEGFA; the disease is breast carcinoma.